臨床外科75巻10号

2020年10月発行

特集 ガイドラインには書いていない—胃癌治療のCQ

—免疫療法の展望—ニボルマブは今後も3次治療で，単剤で使用すべき薬剤なのか？

著者： 河野浩二¹

所属機関： ¹福島県立医科大学消化管外科学講座

ページ範囲：P.1190 - P.1194

【ポイント】
◆胃癌治療ガイドライン（第5版）では，切除不能進行・再発胃癌に対して，3次治療以降に，ニボルマブ単剤による化学療法がエビデンスレベルAで推奨されている．
◆一次治療としてのニボルマブ＋SOX/CapeOXの効果を検証するATTRACTION-4試験が実施中で，第Ⅱ相部分の結果は良好であり，第Ⅲ相のRCTの結果が待たれる．
◆胃癌におけるニボルマブは，奏効率向上のための併用療法の開発と，biomarker-oriented個別化医療の両方向への発展が大きく期待される．

参考文献

1）Koizumi W, Narahara H, Hara T, et al：S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer（SPIRITS trial）：a phase Ⅲ trial. Lancet Oncol 9：215-221, 2008

2）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomised controlled trial. Lancet 376：687-697, 2010

3）Fuchs CS, Tomasek J, Yong CJ, et al：Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma（REGARD）：an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383：31-39, 2014

4）Kang YK, Boku N, Satoh T, et al：Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens（ONO-4538-12, ATTRACTION-2）：a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017

5）Japanese Gastric Cancer A：Japanese gastric cancer treatment guidelines 2014（ver. 4）. Gastric Cancer 20：1-19, 2017

6）Kono K, Nakajima S, Mimura K：Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer 23：565-578, 2020

7）Kono K, Mimura K, Kiessling R：Immunogenic tumor cell death induced by chemoradiotherapy：molecular mechanisms and a clinical translation. Cell Death Dis 4：e688, 2013

8）Boku N, Ryu MH, Kato K, et al：Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer：interim results of a randomized, phase Ⅱ trial（ATTRACTION-4）. Ann Oncol 30：250-258, 2019

9）Aoto K, Mimura K, Okayama H, et al：Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma. Oncol Rep 39：151-159, 2018

10）Kato K, Satoh T, Muro K, et al：A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens（ONO-4538-12, ATTRACTION-2）. Gastric Cancer 22：344-354, 2019

11）Suzuki Y, Mimura K, Yoshimoto Y, et al：Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72：3967-3976, 2012